CD69 Monoclonal Antibody (H1.2F3), FITC, eBioscience™, Invitrogen™

Description

• Description: The H1.2F3 monoclonal antibody reacts with mouse CD69, also known as very early activation antigen (VEA)
• CD69 is approximately 35 kDa and is expressed on the surface as a disulfide-linked dimer
• While a small subset of lymphocytes in the thymus, spleen and lymph nodes express this antigen, activation of both T and B cells rapidly upregulates the surface expression of CD69, suggesting a role for CD69 in lymphocyte development and activation
• Applications Reported: The H1.2F3 antibody has been reported for use in flow cytometric analysis
• Applications Tested: The H1.2F3 antibody has been tested by flow cytometric analysis of resting and activated mouse splenocytes
• This can be used at less than or equal to 0.5 μg per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• Excitation: 488 nm; Emission: 520 nm; Laser: Blue Laser
• Filtration: 0.2 μm post-manufacturing filtered
• CD69 (AIM, Active Inducer Molecule) is a gp28/34 disulfide bonded homodimer with a molecular weight of 60 kDa under non-reducing conditions
• CD69 contains one or two N linked oligosacaride and the molecule is present on activated platelets
• In normal peripheral blood a variable percentage of cells express the CD69 antigen, and it is involved in lymphocyte signal transduction
• Expression CD69 is induced upon activation of T lymphocytes, and may play a role in proliferation
• Furthermore, the protein may act to transmit signals in natural killer cells and platelets
• Alternative splicing results in multiple transcript variants of CD69
• Diseases associated with CD69 dysfunction include coccidiodomycosis and asthma.